Alone in the USA, Novo Nordisk has sold Wegovy for 24.7 billion kroner in the first half of the year. This is 37 percent more than the same period the year before. (Archive photo). Photo: Hollie Adams/Reuters
Novo more than quadrupled Wegovy sales outside the US
Novo Nordisk experienced a 78% growth in global sales of its weight-loss drug Wegovy in the first half of 2025, adjusted for currency fluctuations, totaling 36.9 billion kroner. In the U.S., sales increased by 37% to 24.7 billion kroner, while outside the U.S., sales grew 335% to 12.2 billion...
Get full access to Danish News in English
Gain exclusive access to daily news updates in English pertaining to Denmark with a Ritzau News subscription.
Already a subscriber?